SCHEMBL19334337

SCHEMBL19334337

O=C(Cn1cnc([N+](=O)O)n1)N/N=C/c1cc(Cl)ccc1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.84
HTT P42858 8/20 0.84
L3MBTL1 Q9Y468 7/20 0.84
LMNA P02545 4/20 0.84
CYP1A2 P05177 1/20 0.62
CYP2C9 P11712 1/20 0.62
ALDH1A1 P00352 3/20 0.60
MAPT P10636 6/20 0.59
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 2/20 0.49
KMT2A Q03164 9/20 0.47
MEN1 O00255 8/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MITF O75030 1/20 0.47
GPR174 Q9BXC1 1/20 0.47
KDM1A O60341 1/20 0.46
HPGD P15428 1/20 0.45
POLB P06746 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15679885 0.91 KDM4E (1.00) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL19334358 0.85 KDM4E (0.62) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL19334446 0.84 KDM4E (0.83) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL19334538 0.83 KDM4E (0.67) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL17232446 0.79 KDM4E (0.72) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL19334338 0.77 L3MBTL1 (0.58) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL13401499 0.77 KDM4E (0.75) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL19334422 0.76 KDM4E (0.62) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL15679880 0.75 KDM4E (0.67) KDM4EHTTL3MBTL1LMNACYP1A2
SCHEMBL14958575 0.75 KDM4E (1.00) KDM4EHTTL3MBTL1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed